ALERS Eurobio-Scientific SA

2019 FINANCIAL COMMUNICATION CALENDAR

2019 FINANCIAL COMMUNICATION CALENDAR

2019 FINANCIAL COMMUNICATION CALENDAR

Paris, January 8, 2019 – 5.45 pm

Eurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), leading French group in the field of specialty in vitro medical diagnostics, announces its financial communication calendar for the next year:

  • 2018 Turnover: January 29, 2019
  • 2018 Annual results: April 16, 2019
  • Annual Shareholders meeting: June 25, 2019
  • 2019 Half-year turnover: July 23, 2019
  • 2019 Half-year results: October 15, 2019

Calendar may be subject to change and is communicated on an indicative basis.

Upcoming financial meeting

2018 Turnover: January 29, 2019

About Eurobio Scientific



Eurobio Scientific (ex Diaxonhit) is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 120 employees and two production units based in the Paris region and in the United States.



 



For more information, please visit:



 



The company is publicly listed on the Euronext Growth market in Paris



Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices.



Symbol : ALERS - ISIN Code: FR0013240934  -  Reuters : ALERS.PA  - Bloomberg : ALERS:FP



 



 
Contacts



Eurobio Scientific Group



Denis Fortier, General Manager



Hervé Duchesne de Lamotte, General Manager



Tel. 80



 
Calyptus



Sophie Levesque / Mathieu Calleux



Investor Relations



Tel. 68 -

Attachment

EN
08/01/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eurobio-Scientific SA

 PRESS RELEASE

EUROBIO SCIENTIFIC: 2023 ANNUAL RESULTS

EUROBIO SCIENTIFIC: 2023 ANNUAL RESULTS 2023 ANNUAL RESULTS Growth in Core Business and strategic deployment Core business1 revenues up 39% to €130m proprietary products account for 30% of revenues38% of revenues generated outside France Resilient results within a strategic transformation phaseFree cash flow of €26.4mNet financial debt reduced to €5.5m, with €89m cash position Paris, April 10, 2024 - 5.40pm - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today announced its consolidated annual results for 2023, prepa...

 PRESS RELEASE

EUROBIO SCIENTIFIC: RESULTAT ANNUEL 2023

EUROBIO SCIENTIFIC: RESULTAT ANNUEL 2023 RESULTAT ANNUEL 2023 Croissance du cœur d’activité et déploiement stratégique Chiffre d’affaires Cœur d’activité1 en croissance de 39% à 130 M€ les produits propriétaires atteignent 30% du CAla part du CA hors France est de 38% Bonne résistance des résultats dans un contexte de transformation stratégiqueFlux de trésorerie disponible après investissement de 26,4 M€Dette financière nette réduite à 5,5 M€, avec une trésorerie de 89 M€ Paris, le 10 avril 2024 - 17h40 - Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader ...

 PRESS RELEASE

Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE ...

Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39%Successful deployment of the Group's strategy: Proprietary products up at 30% of revenuesInternationalization, with 38% of revenues now generated outside of France Acquisition of DID in Italy effective as of July 1st, 2023Acquisition of Alpha Biotech, GenDx distributor, effective as of January 3rd, 2024 Paris, January 30, 2024 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a ...

 PRESS RELEASE

Eurobio Scientific : EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION ...

Eurobio Scientific : EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE Progression du chiffre d’affaires annuel cœur d’activité à +39%Succès du déploiement de la stratégie du Groupe : Produits propriétaires : 30% du Chiffre d’affairesInternationalisation : 38% du Chiffre d’affaires réalisé hors de France  Acquisition de DID (Italie) effective depuis le 1er juillet 2023Acquisition d’Alpha Biotech, distributeur de GenDx au Royaume-Uni depuis le 3 janvier 2024 Paris, le 30 janvier 2024 – 17h45 Eurobio Scientific (FR00...

 PRESS RELEASE

Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE

Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE Paris, le 17 janvier 2024 – 17h45 Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe), les moyens suivants figuraient au compte de liquidité à la date du 29/12/2023 : 20,366 titres116,011.44 euros en espèce Au cours du 2nd semestre 2023, il a été négocié un total de : ACHAT17,489 titres263,599.82 EUR243 transactionsVENTE58,626 titres313,497.40 EUR206 transactions Il est rappelé que lors du ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch